



Relationship Between Odor Intensity Estimates and COVID-19 Prevalence Prediction in a Swedish Population

Behzad Iravani, Artin Arshamian, Aharon Ravia, Eva Mishor, Kobi Snitz, Sagit Shushan, Yehudah Roth, Ofer Perl, Danielle Honigstein, Reut Weissgross, et al.

► To cite this version:

Behzad Iravani, Artin Arshamian, Aharon Ravia, Eva Mishor, Kobi Snitz, et al.. Relationship Between Odor Intensity Estimates and COVID-19 Prevalence Prediction in a Swedish Population. *Chemical Senses*, 2020, 45 (6), pp.449-456. 10.1093/chemse/bjaa034 . hal-03060264

HAL Id: hal-03060264

<https://hal.science/hal-03060264>

Submitted on 15 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Original Article

Relationship Between Odor Intensity Estimates and COVID-19 Prevalence Prediction in a Swedish Population

Behzad Iravani^{1,*}, Artin Arshamian^{1,2,*}, Aharon Ravia³, Eva Mishor³, Kobi Snitz³, Sagit Shushan^{3,4}, Yehudah Roth⁴, Ofer Perl³, Danielle Honigstein³, Reut Weissgross³, Shiri Karagach³, Gernot Ernst⁵, Masako Okamoto⁶, Zachary Mainen⁷, Erminio Monteleone⁸, Caterina Dinnella⁸, Sara Spinelli⁸, Franklin Mariño-Sánchez⁹, Camille Ferdenzi¹⁰, Monique Smeets¹¹, Kazushige Touhara⁶, Moustafa Bensafi¹⁰, Thomas Hummel¹², Noam Sobel³ and Johan N. Lundström^{1,13}

¹Department of Clinical Neuroscience, Karolinska Institutet, Nobels väg 9, 17177 Stockholm, Sweden, ²Department of Psychology, Stockholm University, Frescati hagväg, 114 19 Stockholm, Sweden, ³Department of Neurobiology, Weizmann Institute of Science, 234 Herzl Street, Rehovot 76100, Israel, ⁴Department of Otolaryngology—Head and Neck Surgery, Edith Wolfson Medical Center, P.O. Box 5, 58100 Holon, Israel, ⁵Vestre Viken, Kongsberg Hospital and Psychological Institute, University in Oslo, Forskningsveien 3A, 0373 Oslo, Norway, ⁶Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan, ⁷Champalimaud Research, Champalimaud Centre for the Unknown, Av. Brasília, 1400-038 Lisbon, Portugal, ⁸Department of Agriculture, Food, Environment and Forestry, University of Florence, via Donizetti 6, Florence 50144, Italy, ⁹Rhinology and Skull Base Surgery Unit, Otorhinolaryngology Department, Ramón y Cajal University Hospital, Ctra. de Colmenar Viejo km. 9.100, 28034 Madrid, Spain, ¹⁰Lyon Neuroscience Research Center, CNRS—INSERM—University Claude Bernard of Lyon, 95 bd Pinel, 69500 Bron, France, ¹¹Faculty of Social and Behavioral Sciences, Utrecht University, Heidelberglaan 2, 3584 CS Utrecht, the Netherlands, ¹²Smell and Taste Clinic, Department of Otorhinolaryngology, TU Dresden, Fetscherstrasse 74, 01307 Dresden, Germany and ¹³Monell Chemical Senses Center, 3500 Market Street, Philadelphia, 19104 PA, USA

*These authors contributed equally to the work.

Correspondence to be sent to Johan N. Lundström, Department of Clinical Neuroscience, Karolinska Institutet, Nobels väg 9, 17177 Stockholm, Sweden. e-mail: johan.lundstrom@ki.se

Editorial Decision 19 May 2020.

Abstract

In response to the coronavirus disease 2019 (COVID-19) pandemic, countries have implemented various strategies to reduce and slow the spread of the disease in the general population. For countries that have implemented restrictions on its population in a stepwise manner, monitoring of COVID-19 prevalence is of importance to guide the decision on when to impose new, or when to abolish old, restrictions. We are here determining whether measures of odor intensity in a large sample can serve as one such measure. Online measures of how intense common household odors are perceived and symptoms of COVID-19 were collected from 2440 Swedes. Average odor intensity ratings were then compared to predicted COVID-19 population prevalence over time in

the Swedish population and were found to closely track each other ($r = -0.83$). Moreover, we found that there was a large difference in rated intensity between individuals with and without COVID-19 symptoms and the number of symptoms was related to odor intensity ratings. Finally, we found that individuals progressing from reporting no symptoms to subsequently reporting COVID-19 symptoms demonstrated a large drop in olfactory performance. These data suggest that measures of odor intensity, if obtained in a large and representative sample, can be used as an indicator of COVID-19 disease in the general population. Importantly, this simple measure could easily be implemented in countries without widespread access to COVID-19 testing or implemented as a fast early response before widespread testing can be facilitated.

Key words: anosmia, coronavirus, COVID-19, olfactory dysfunction, population prevalence

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has, since its first discovery at the end of the year 2019, rapidly spread across countries (Zhu et al. 2020). In sharp contrast to the majority of western European countries, the Swedish authorities have opted to not close down the majority of society as a response to the COVID-19 pandemic. Instead, the Swedish authorities have, in a stepwise fashion, limited the curtailing of normal individual rights to basically 4 major actions: international travel ban, a ban on public gatherings of more than 50 individuals (down from an initial ban of >500 individuals), forced universities and high schools (students aged above age of 16) to switch to online teaching, and, recently, a mandate that restaurants and bars offer table service only (Swedish Public Health Authority 2020b). In addition, the Swedish Public Health Authority has recommended that individuals work from home, if possible, and has promoted the practice of physical distancing, recommendations that are largely respected. The Swedish response to the pandemic can be summarized as a tactic of stepwise implementation of measures in response to the predicted prevalence of COVID-19. This strategy as a response to a pandemic is, however, dependent on the nontrivial problem of identifying a reliable measure of COVID-19-positive individuals in the population, data of vital importance for the timing of government action to slow the spread of the disease.

Recent reports have demonstrated that inquiries on search engines for salient COVID-19 symptoms can serve as a potential indicator of COVID-19 prevalence in the population (Walker et al. Forthcoming). However, the clinical symptoms of COVID-19 are diffuse (World Health Organization 2020), which limits the precision of online searches. While the list of identified symptoms has evolved, several recent reports suggest that olfactory dysfunction may be a specifically salient and potentially early symptom of COVID-19 (Gane et al. forthcoming; Menni et al. forthcoming). If so, olfactory dysfunction might be a key symptom that can potentially be used as an efficient tool to estimate the prevalence of COVID-19 positive cases in a population. The reported prevalence of olfactory dysfunction in relation to COVID-19 has ranged from around 5% (Mao et al. forthcoming) to a full 98% (Moein et al. forthcoming). Reports based on a retrospective review of medical records have generally reported lower prevalence numbers, whereas the majority of publications using self-reported olfactory problems have indicated prevalence numbers around 60% (ranging from 30% to 88%; cf. Pellegrino et al. forthcoming). This large variation between studies can be attributed to both difference in how olfactory dysfunction was assessed and defined and to what sample (clinical or general population) was recruited to the various studies. It is not surprising then that studies only including COVID-19 patients demonstrate a larger prevalence of olfactory dysfunction compared to studies with an open inclusion, irrespective of established diagnosis or type of

symptoms experienced. Nonetheless, there are currently several peer-reviewed and nonpeer-reviewed reports that consistently indicate that olfactory dysfunction is a salient symptom of COVID-19 (cf. Pellegrino et al. forthcoming). Importantly, the Swedish Public Health Authority recently identified olfactory dysfunction as the most prevalent symptom in the Swedish COVID-19 population estimate. Taken together, this indicates that olfactory dysfunction is a good marker for COVID-19 occurrence.

The relationship between self-assessed and psychometrically assessed olfactory function is, however, low (Landis et al. 2003). While most people can notice sudden changes in olfactory function, awareness of an olfactory loss is still far lower than a perceptual loss in other sensory modalities, such as audition and vision. It is, therefore, necessary to reliably estimate olfactory loss by probing olfactory functions with actual odors. The majority of clinical tests for odor dysfunction use an easily administrated and time-efficient method of assessing an individual's ability to identify odor (Kobal et al. 1996). However, to create odor identification tests for home use is a problematic undertaking given that the tested individual should not know which odors are included in the test and because test–retest learning is a considerable confound. Moreover, the use of free odor identification is difficult even for normosmic individuals, meaning that written or verbal cues in combination with lures are needed, therefore, making language skill and language comprehension confounding factors. Together, these problems render odor identification suboptimal as a home test. A more straightforward test might, therefore, be to assess odor intensities of common household odors, thereby avoiding the limitations imposed by verbalization. Indeed, using the assessment of odor intensities as a measure of olfactory functions has previously been used (Stamps et al. 2013) and demonstrated to be related to odor detection thresholds of the odor in question (Kern et al. 2015). Few household odors are, however, only activating the olfactory system (Lundström et al. 2011). The overwhelming majority of odors stimulate both the olfactory and the so-called trigeminal nerve and produce a feeling of nasal irritation in addition to the odor percept (Lundström et al. 2012). It is not known if the trigeminal nerve is affected by the SARS-CoV-2 virus, and a potential home-made test needs to account for this possibility. Here, we will assess whether odor intensity ratings can be used as a measure of COVID-19 spread in the population. We do this by using data from a Swedish population to determine whether a home-based odor intensity rating can predict population prevalence of COVID-19 in Sweden. This data comes from a multicenter project initiated at the Weizmann Institute of Science with the overall aim of determining the involvement of the olfactory system in the COVID-19 disease. Via an online rating tool (www.smelltracker.org), participants rate household odors for their perceived intensity and pleasantness. Specifically, we determine whether odor intensity ratings negatively

follow predicted population prevalence of COVID-19 and whether odor intensity ratings are modulated by COVID-19 symptoms. We hypothesized that, in a larger sample, odor intensity ratings over time would follow the prevalence of COVID-19 in the general population and, therefore, be of potential use as a predictor.

Methods

Participants

A total of 2930 unique individuals entered the data collection website smelltracker.org, identified themselves as Swedish, and provided information about their sex and age. In our analyses, we removed: 33 individuals that indicated an age below 18, 374 individuals who did not provide any odor ratings, and 83 individuals that rated all odor intensities above 95 (on a 0–100 scale, see below for scale information) on suspicion of not following/understanding the task. This meant that our final sample consisted of a total of 2440 individuals (mean age 47.4 years, ± 14.11 standard deviation [SD], range 18–99). In the final sample, a total of 1680 individuals identified themselves as a woman and 760 as a man. Data collection and analyses were approved by both the Israeli Edith Wolfson Medical Centre Helsinki Committee and the Swedish Institutional Review Board (Etikprövningsnämnden, 2020-01577). Participants did not receive any form of monetary compensation for their participation, and consent was waived. All aspects of the study complied with the Declaration of Helsinki for Medical Research involving Human Subjects.

Recruitment strategy and participant regional domiciliation

Recruitment for the Swedish population was mainly done by appearances in various local news media in the Stockholm regions and outreach initiatives by the Karolinska Institute in Stockholm. Due to the high level of privacy security, no data that could localize the participant other than to the country of residency was obtained; we, therefore, do not know with certainty in what region of Sweden participants were localized at the time of testing. However, judging from COVID-19-related hospitalization rates in the Swedish regions at the time of sampling, the spread of COVID-19 has mostly been centered around the general Stockholm area. The regional specificity in both COVID-19 spread and recruiting, in combination with the demonstrated association between our obtained data and COVID-19

prediction in the Stockholm area (see Results), we believe that the vast majority of participants were from the greater Stockholm area.

Procedure

Participants visited the Swedish version of the multilingual website smelltracker.org and provided details regarding age, declared gender (Woman/Man/Other), and whether they have been tested for COVID-19 (No, Yes-Pending, Yes-Positive, and Yes-Negative). They subsequently answered what symptoms of COVID-19, if any, they currently experienced. Available symptoms were: “Fever, Cough, Shortness of breath or difficulty breathing, Tiredness, Aches, Runny nose, Sore throat, Loss of the sense of smell, Loss of taste, No symptoms.” Unique login was created for each individual to facilitate repeated testing.

Next, participants picked 5 odors to rate, each from a separate category with a fixed list of common household odors. We opted to have participants rate 5 odors to strike a balance between increased reliability, where more intensity assessments render more reliable data (Kern et al. 2015), and low burden for participants to facilitate broad participation. The first 2 odor categories were selected to contain odors with little to no trigeminal sensation (unisensory odors), whereas the last 3 categories were odors with mixed sensations of odor and trigeminal in various degree, so-called bimodal odors (Table 1). Participants were instructed to preferentially pick from the top of each list but, if necessary, choose any item that would be available to them going down the list in order. At repeated testing, the same 5 odors, freshly prepared, were to be used. Participants then proceeded to smell each odor and, on a separate page for each odor, rated their perceived intensity and pleasantness on separate visual analog scales ranging from very weak/very unpleasant to very strong/very pleasant, respectively. These scales were coded in the system as ranging from 0 (min) to 100 (max). Participants could smell the odor as often as they liked, and there was no time pressure applied. We are here only focusing on odor intensity ratings.

Population prevalence, palynological data, and seasonal virus control data

We obtained data on the predicted prevalence of COVID-19 in the sample population from the Public Health Agency of Sweden (Folkhälsomyndigheten) (Swedish Public Health Authority 2020a). From March to April, Folkhälsomyndigheten randomly sampled 738

Table 1. Odor categories with the alternatives available for participants to choose from

Category 1	Category 2	Category 3	Category 4	Category 5
Vanilla extract	Peanut butter	Mustard (Dijon)	Garlic (chopped)	Toothpaste
Nutella	Coconut oil	Vinegar (white)	Camembert cheese	Hand soap
Honey	Olive oil	Horseradish (jar)	Canned tuna	Laundry detergent
Strawberry jam	Basil	Wasabi	Blue cheese	Shampoo
Apricot jam	Oregano	Onion (chopped)	Canned sardines	Hand cream
Apple juice (not fresh)	Parsley	Vinegar (apple)	Mushrooms	Body lotion
Orange juice (not fresh)	Cilantro	Black pepper (ground)	Boiled egg	Perfume
Lemonade (not fresh)	Dill	Menthol gum	Pickled herring	Hand sanitizer
Peach nectar (not fresh)	Cardamom	Mint (fresh)	Cumin	Sunscreen
Pear nectar (not fresh)	Thyme	Mint (gum)	Soy sauce	Baby oil
Grapefruit juice (not fresh)	Nutmeg	Mint (tea)	Sauerkraut (jar)	
Pineapple juice (not fresh)	Caraway	Sesame oil	Coffee (ground)	
Banana nectar (not fresh)	Bay leaves	Vodka	Coffee (instant)	
Cinnamon	Ketchup	Clove	Tea (black)	
Maple syrup	Peanut butter	Vinegar (balsamic)	Tea (earl gray)	

Categories 1 and 2 contain items with odors that are low in trigeminal irritation, whereas categories 3–5 contain odors with a higher trigeminal irritation factor.

individuals in the Stockholm region and, based on this data, together with available data from the health care system and the contagion factor of the SARS-CoV-2 virus, modeled the prevalence of COVID-19 in the Stockholm population over time. The model is a fitted compartmental Susceptible–Exposed–Infectious–Recovered model that assumes unreported cases as 98.7% of infected and their infectivity as 55% compared to reported cases. Model details, raw data, scripts, and figures for the updated model (version 2), which were used as a predictor in this manuscript, can be obtained from an open data deposit: <https://github.com/FohmAnalys/SEIR-model-Stockholm>.

A potential confounding variable in this Swedish sample is the co-occurrence of the COVID-19 pandemic with the onset of the Swedish pollen season. In other words, a potential shift in rated intensity over time could be mediated by an increase in allergic rhinitis due to a rise in levels of airborne pollen. We, therefore, obtained airborne pollen data for the Stockholm area from the Palynological Laboratory at the Swedish Museum of Natural History. Because we do not have data on the prevalence of potential allergic rhinitis (pollen allergy) or what specific allergies participants had, we summed up the values of all allergenic pollen for each day of measurement. During the time period of our sampling, there was airborne pollen detected from 3 species; Alder (*Alnus*), Birch (*Betula*), and Hazel (*Corylus*).

Another potential confounding variable is the occurrence of seasonal viruses, such as seasonal influenza or gastroenteritis-causing viruses, which might cause a reduction in odor intensity measures given the overlap between their seasonal occurrence and the SARS-CoV-2 outbreak. Prevalence data of these common virus outbreaks are impossible to obtain because only cases needing hospitalization are reported. However, one of the more commonly reported viruses is the gastroenteritis-causing virus *Caliciviridae*. To estimate the prevalence of seasonal viruses, data was obtained from the Public Health Agency of Sweden (Folkhälsomyndigheten) of reported laboratory-confirmed cases of *Caliciviridae* for the current season and the 2 previous ones as comparison.

Data reduction and statistical analyses

To match the results of the COVID-19 prediction model and to increase the reliability of the collected intensity ratings, values were averaged in 3-day intervals. Single cases of missing values were replaced with the median of that specific odor category. Odor ratings were then averaged across odors. For analyses of global odor intensity, all categories were averaged; for ratings of unisensory odors, categories 1 and 2 were averaged and, for ratings of bimodal odors, categories 3–5 were averaged. For individuals reporting more than one testing session, only the first testing session was included for these specific analyses.

Associations between odor intensity ratings and COVID-19 prediction model, as well as odor intensity and COVID-19 symptoms, were assessed by Spearman rank correlations. To identify olfactory dysfunction threshold, a cutoff of the 10th percentile of odor intensity within the subpopulation that reported no symptom was used as an indication of olfactory symptoms, as is often used for clinical olfactory tests (Hummel et al. 2007). This cutoff value was subsequently used to define the percentage of olfactory dysfunction in other subpopulations, that is (subjectively reported), Symptom, COVID-19 +, and COVID-19 –, the last 2 categories based on lab testing. To maximize the likelihood of identifying individuals with COVID-19 tests, in these analyses, we included all sessions from individuals with repeated testing.

To assess the ability of our measure to identify shifts in potential diagnoses, we identified individuals who had provided data on more than one occasion and, from them, assessed who had progressed from indicating no symptoms to indicating symptoms in a subsequent session. Their ratings in the session just before the session indicating symptoms were used as their nonsymptomatic score and their ratings in the first session indicating symptoms were used as their symptomatic scores. A paired 2-tailed Student's *t*-test was used to assess odor intensity rating predeveloping and postdeveloping COVID-19 symptoms. Finally, for the test–retest reliability, we used a Pearson correlation between odor intensity ratings in the first session and second session in individuals who provided data in more than 1 session and who reported no symptoms in both. All other correlation tests were done with Spearman correlation to avoid the influence of skewed data. All statistical analyses were carried out within the MATLAB (version 2019b) environment with Statistical and Machine Learning toolbox.

Results

Relationship between COVID-19 prevalence and odor intensity perception

We assessed the development of olfactory abilities over time by plotting mean intensity perception per day against the predicted prevalence of COVID-19 in the Stockholm population. Over the testing time, mean odor intensity ratings decline, whereas the predicted COVID-19 societal levels go up (Figure 1A). There was a marked downward shift in ratings of odor intensity levels occurring in this sample between 4 and 9 April. To assess whether this function was different for odors with low and high trigeminal irritants (unisensory and bimodal odors), we assessed them separately. We found that both the unimodal odor category (Figure 1B) and the bimodal odor category (Figure 1C) had similar psychometric functions. We then assessed the statistical relationship between intensity estimates over time and population COVID-19 predictions using Spearman rank correlation. There was a significant negative relationship between the COVID-19 prediction model and odor intensity ratings over time, $\rho = -0.83$, $P < 0.001$ (Supplementary Figure S1). Similarly, there were significant relationships between the COVID-19 prediction model and both the unimodal odor category, $\rho = -0.79$, $P < 0.003$, and the bimodal odor category, $\rho = -0.83$, $P < 0.001$. In other words, odor intensity ratings of common household odors track the estimated prevalence of COVID-19 in the population and the shift in intensity aligned with predicted peak SARS-CoV-2 contagion. This seems independent of whether the odors have more or less trigeminal irritants, which is consistent with the high correlation between ratings of the unisensory and bimodal odors, $\rho = 0.92$, $P < 0.001$.

In this sample, as in the general population, there are healthy individuals who might have done the odor testing as a potential screening tool for COVID-19. We, therefore, wanted to assess the potential influence of COVID-19 symptoms on odor intensity ratings. To this end, we first divided the sample into individuals who reported no COVID-19 symptoms and individuals who reported at least one of the listed symptoms. There was a clear separation in odor intensity perception between the 2 groups across time (Figure 1D). Moreover, the more symptoms the individual reported, the weaker the odors were perceived as, as demonstrated by a Spearman correlation between the number of reported COVID-19 symptoms and odor intensity ratings, $\rho = -0.29$, $P < 0.001$ (Figure 2). All symptoms reported by participants who did report




Figure 1. Odor intensity perception relate to COVID-19 prevalence. (A) Mean intensity ratings of the 5 odor categories (blue line and axis) in relation to population prediction (black line and axis) of COVID-19 prevalence in the Stockholm region. (B) Mean intensity ratings of unimodal odors (odor categories 1 and 2; blue line and axis) in relation to population prediction of COVID-19 prevalence in the Stockholm region. (C) Mean intensity ratings of bimodal odors (odor categories 3–5; blue line and axis) in relation to population prediction of COVID-19 prevalence in the Stockholm region. (D) Mean intensity ratings of odors (categories 1–5), separated into individuals without (green squares, blue axis) and with (purple squares, blue axis) reported COVID-19 symptoms, in relation to population prediction (black line and axis) of COVID-19 prevalence in the Stockholm region. Error bars in all panels indicate standard error of the mean (SEM). Error bars for first day of testing are large due to few participants that day.




Figure 2. Odor intensity perception relates to COVID-19 symptoms. Individual mean rated intensity of odors in relation to number of reported COVID-19 symptoms, excluding loss of smell/taste. Dots represent individuals and red dotted line indicates the regression line. Blue color indicates the number of overlapping individuals.

symptoms, aggregated over dates reported in Figure 1, can be found in (Supplementary Table S1).

Reduction in odor intensity estimates can occur due to other reasons that are not COVID-19 related, for example, a blocked nose due to seasonal allergy or due to other seasonal virus diseases, such as influenza or gastroenteritis viruses. To assess whether there was a relationship between intensity levels and either pollen levels or incidence of seasonal viruses, we first plotted the change in odor intensity ratings over time compared to daily summarized levels of measured airborne pollen from all the known allergenic species detected at the time in the Stockholm area. There was a clear increase in summated pollen levels toward the end of our sampling period (Supplementary Figure S2). However, this increase in summated

pollen levels occurred at a later time point than the marked downward shift in ratings of odor intensity levels occurring in this sample between 4 and 9 April. We then assessed the incidence of reported confirmed cases during the flu season 2019–2020 of the common gastroenteritis-causing virus, *Caliciviridae*, in relation to the 3 past seasons. At the time when testing began for the present data, there had already been a sharp reduction in reported cases of *Caliciviridae* infections (Supplementary Figure S3), likely a consequence of the preventive measure implemented to reduce transmission of the SARS-CoV-2 virus. It can be assumed that similar trends would be seen for other seasonal virus outbreaks.

Higher prevalence of olfactory dysfunction among individuals with COVID-19 symptoms

Having established that there is a clear difference in odor intensity perception between individuals with and without COVID-19 symptoms, we wanted to know what the prevalence of olfactory dysfunction was in the overall sample and the different subsamples. We defined olfactory dysfunction as mean odor intensity ratings falling below the 10th percentile in the group reporting no COVID-19 symptoms, a definition that is aligned with other attempts of assessing the prevalence of olfactory dysfunction (Hummel et al. 2007). This is of course a conservative measure that will bias our estimates toward a potential lower prevalence given that there might be asymptomatic COVID-19 patients or individuals with olfactory dysfunction prior to the COVID-19 pandemic. Applying this cutoff to the group that displayed symptoms of COVID-19, 66% of these individuals had intensity estimates falling in the olfactory dysfunction category




Figure 3. Olfactory dysfunction in relationship to COVID-19 symptoms. **(A)** Percentage of olfactory dysfunction within subsample that indicated either COVID-19 symptoms (sessions, $n = 2469$) or had undergone COVID-19 testing (Covid-19 + = positive [$n = 16$], Covid-19 - = negative [$n = 25$]). **(B)** Shift in intensity ratings between sessions for individuals that progressed from indicated “No Symptoms” to indicating “Symptoms”. Dots indicate individual values ($n = 107$) and lines connects the values for the same individual. Error bars indicate standard error of the mean (SEM).

(Figure 3A). However, having symptoms of COVID-19 does not constitute a diagnosis meaning that odor dysfunction in the sample cannot be directly linked to confirmed COVID-19 diagnosis. The national strategy of the Swedish national health care system has been to prioritize testing of individuals admitted to a hospital with clear signs of a SARS-CoV-2 infection. This means that few individuals in our sample had been tested for COVID-19 and even fewer had a positive test. However, 16 individuals indicated that they had been confirmed as COVID-19 and, among these individuals, 81% was classified as part of the olfactory dysfunction group (Figure 3A). Among the individuals that had in the past been confirmed as COVID-19 negative, 32% were classified in the olfactory dysfunction group.

A subsample visited the website on multiple occasions and provided intensity estimates on repeated occasions. This provided us the opportunity to observe when individuals progressed from indicating “No Symptoms” to indicating one or more symptoms in subsequent testing (Figure 3B). A total of 107 individuals made this transition at some point during testing. We then compared their mean intensity rating of the unisensory odors during the last session they indicated “No Symptoms” with that of the first session they started to indicate symptoms. On the group level, there was a significant difference between the 2 sessions, $t(103) = 6.15$ $P < 0.001$, with an average of 20 points (29%) reduction in odor intensity on the 100-point visual analog rating scale. Mean time elapsed between the 2 sessions of interest was 1.82 (SD = 2.64) days.

Test–retest reliability

Finally, we determined the test–retest reliability of the odor intensity measure by assessing the relationship between odor ratings in their first session and their second session within individuals that performed more than 1 testing session and who reported no symptoms in either one of the sessions ($n = 130$). A Spearman correlation

test indicated a decent test–retest coefficient of 0.66, $\rho(128) = 0.66$, $P < 0.0001$.

Discussion

We can here demonstrate that ratings of odor intensity from a larger group within an area of COVID-19 outbreak closely follow the predicted prevalence of COVID-19 over time. We can demonstrate not only that odor dysfunction is associated with symptoms of COVID-19 but also that, when an individual progresses from indicating no COVID-19 symptoms to listing COVID-19 symptoms, there is a significant drop in odor intensity as soon as the next testing session. These results suggest that simple perceptual ratings of odors can serve as a future tool to predict levels of COVID-19 infection within a population.

Home testing of odor functions during a pandemic needs to be easy both to implement and to explain to the individual. Intensity ratings of widely available household products via online assessment is a simple and cheap way both for the individual to obtain the indication of odor dysfunction, which might indicate COVID-19 onset, and for a potential governmental or health organization to monitor the spread of the disease. Participants in this study had to choose between set classes of odors, but this may not be necessary if the main aim is to determine COVID-19 spread based on intensity estimates. Intensity ratings for the odor categories containing odor sources with low trigeminal irritants and the categories containing odor sources with a bimodal sensation both closely followed the predicted COVID-19 prevalence (correlation coefficients 0.79 and 0.83, respectively). Few household odors beyond vanillin are truly activating only the olfactory system without any trigeminal activation and attempting to only use low trigeminal odors might lower the ease of use; therefore, a more feasible setup might be to allow free selection and instead block certain odor sources with a known

high trigeminal activation. It is at the present time unclear if the SARS-CoV-2 virus affects the olfactory system, alone, or whether the trigeminal system is also influenced. The fact that bimodal odors, as well, closely track the COVID-19 spread in the population lends support to the notion that the trigeminal system may also be affected either by the SARS-CoV-2 virus or by the reduced olfactory ability per se (Frasnelli et al. 2007). However, although the odors listed in the bimodal odor categories are bimodal in their percept, most are not strong trigeminal irritants. Whether similar results would be obtained using stronger irritants, such as acetone, remains to be determined.

Of the 16 individuals with confirmed COVID-19, 81% had intensity ratings low enough to fall in the olfactory dysfunction category. Even though this result is higher than what has been reported in studies based on self-reports, this high number is aligned with a recent study that tested actual olfactory function in confirmed COVID-19 positive patients (Moein et al. forthcoming). At the time of the study, the Swedish health authorities prioritized testing of COVID-19 in individuals when admitted to a hospital with signs of COVID-19 and key health care staff. This has led to a low number of individuals with confirmed COVID-19 status which is a major weakness of the study. We can, therefore, not conclusively state that all individuals with symptoms of COVID-19 indeed were COVID-19 positive. We did find, however, that the number of listed symptoms was negatively associated with odor intensity and there was, on average, a large drop in odor intensity perception when an individual transgressed from reporting no symptoms to reporting symptoms.

Still, it is important to note that a shift in odor intensity perception is not by itself a diagnosis of COVID-19 and future studies addressing links between COVID-19 and olfactory perception should, if possible, test individuals with established COVID-19 status to obtain the exact measure of its specificity. It is also important to note that these odor intensity measures cannot provide a clinical diagnose of olfactory disorders, albeit real odors are used and not only via meta-perceptual self-assessment, a measure that is less reliable. That said, a major benefit of the study is the demonstration that ratings of odor intensities do track COVID-19 population prevalence, which could potentially be of use in countries where in-field testing is not available or at initial stages of a potential future outbreak of coronavirus that might have similar effects on the olfactory system and where the development and buildup testing capacity has yet to happen.

The marked drop in olfactory functions between sessions when participants started to report COVID-19 symptoms suggests that odor measures might serve as a clear indicator of COVID-19 at an individual level beyond the population level demonstrated here. However, the test–retest reliability of odor intensity measure, here estimated to 0.66, indicates that odor intensity function might not work as a reliable measure on the individual level and assessments should be reserved to the group level. Moreover, in-home testing using self-administration and online reporting will always be inferior to testing in the lab by a well-trained experimenter. That said, other studies assessing test–retest of odor intensities have reached a near-identical value in a lab testing setting (Kern et al. 2015), thereby indicating that the obtained measures correspond to other more controlled collections. At this time, it is, however, unlikely that mere intensity estimates could serve beyond the indication of a potential COVID-19 diagnosis, which should either trigger serum testing of COVID-19 or for health care workers to treat a patient as a potential COVID-19 suspect. Nonetheless, there is great potential for the development of odor tests of COVID-19 that might reach a specificity near serum tests.

In the general debate whether olfactory dysfunction is a sign of COVID-19, a valid counterargument has been raised that loss of olfactory function is not uncommon for other seasonal viruses and the significantly larger prevalences of olfactory dysfunction reported for the SARS-CoV-2 virus might be explained by the increased attention to symptoms and an increase in response prevalence. Seasonal viruses do commonly lead to a reduction of olfactory function or anosmia (total loss of olfactory functions; Seiden 2004) and virus infection is one of the leading causes of anosmia in patients with nonconductive olfactory disorders (Quint et al. 2001). However, the prevalence of seasonal viruses in Sweden was greatly reduced in response to the preventive measures implemented by the Swedish authorities before our data was collected (Supplementary Figure S3). It is also worth highlighting that a full 81% of the individuals who tested positive for COVID-19 in our sample were classified as having olfactory dysfunction. This is an incidence that is far greater than what is commonly observed for other upper respiratory infections (Seiden 2004). A salient aspect of COVID-19-related olfactory dysfunction seems to be the frequent report of an isolated sudden onset in the absence of other nasal problems with patients reporting a normal nasal patency (Gane et al. forthcoming). However, it is of interest to point out that our data indicate that the observed decreases in olfactory functions were in most cases accompanied by other symptoms of COVID-19 and there was a clear correlation between the number of reported symptoms and odor intensity estimates. It is, therefore, likely that building a complex model of multiple symptoms provides the best model. That would, however, require clinical testing to establish the reliability of reported symptoms. Nonetheless, the exact mechanism of this onset of olfactory dysfunction without other common symptoms associated with upper respiratory infections, where the lack of nasal blockage is the salient factor, has yet to be determined, but recent data suggest a few hypotheses. Nasal epithelial cells richly express the SARS-CoV-2 entry factor (Sungnak et al. 2020), the ACE2 receptors, which has been linked to both the virus replication rate and disease severity (Hoffmann et al. 2020; Zhou et al. 2020). Based on this, it can be speculated that the SARS-CoV-2 virus damages the olfactory epithelium to such extent that olfactory ability is degraded. Many viruses, including coronaviruses, can also propagate via the olfactory nerve and, thereby, infect and damage the olfactory bulb (Schwob et al. 2001; Wheeler et al. 2017). Coronavirus RNA has been found in olfactory areas of the brain (Li et al. forthcoming), and recent data suggests that some COVID-19 patients display neurological symptoms (Mao et al. forthcoming). Moreover, it is possible that nasal blockage occurs but so high up in the nasal cavity that the blockage only affects access to the olfactory epithelium without impeding nasal patency (Eliezer and Hautefort 2020). Future studies are needed to isolate the exact mechanisms.

In conclusion, we can here demonstrate that measures of odor intensity closely track estimated COVID-19 levels on a population level. This simple measure, if implemented in a large sample within the area of outbreak, could serve as an easy and cheap measure of COVID-19 spread in society. This measure would provide special value to underdeveloped countries where COVID-19 tests might not be widely available or to be implemented in an early phase of a COVID-19 epidemic before widespread testing has been implemented.

Supplementary material

Supplementary material can be found at *Chemical Senses* online.

Funding

This project was supported by an European Research Council AdG grant (SocioSmell, 670798) awarded to N.S. and the writing and analyses by a grant from the Knut och Alice Wallenbergs Stiftelse (KAW 2018.0152) awarded to J.N.L.

References

- Eliez M, Haefliger C. 2020. MRI evaluation of the olfactory clefts in patients with SARS-CoV-2 infection revealed an unexpected mechanism for olfactory function loss. *Acad Radiol*. doi: [10.1016/j.acra.2020.05.013](https://doi.org/10.1016/j.acra.2020.05.013).
- Frasnelli J, Schuster B, Hummel T. 2007. Interactions between olfaction and the trigeminal system: what can be learned from olfactory loss. *Cereb Cortex*. 17(10):2268–2275.
- Gane SB, Kelly C, Hopkins C. Forthcoming. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? *Rhinology*. doi: [10.4193/Rhin20.114](https://doi.org/10.4193/Rhin20.114).
- Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 181(2):271–280.e8.
- Hummel T, Kobal G, Gudziol H, Mackay-Sim A. 2007. Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. *Eur Arch Otorhinolaryngol*. 264(3):237–243.
- Kern DW, Schumm LP, Wroblewski KE, Pinto JM, Hummel T, McClintock MK. 2015. Olfactory thresholds of the U.S. Population of home-dwelling older adults: development and validation of a short, reliable measure. *PLoS One*. 10(3):e0118589.
- Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf S. 1996. “Sniffin’ sticks”: screening of olfactory performance. *Rhinology*. 34(4):222–226.
- Landis BN, Hummel T, Hugentobler M, Giger R, Lacroix JS. 2003. Ratings of overall olfactory function. *Chem Senses*. 28(8):691–694.
- Li Y-C, Bai W-Z, Hashikawa T. Forthcoming. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J Med Virol*. doi: [10.1002/jmv.25728](https://doi.org/10.1002/jmv.25728).
- Lundström JN, Boesveldt S, Albrecht J. 2011. Central processing of the chemical senses: an overview. *ACS Chem Neurosci*. 2(1):5–16. doi: [10.1021/cn1000843](https://doi.org/10.1021/cn1000843).
- Lundström JN, Gordon AR, Wise P, Frasnelli J. 2012. Individual differences in the chemical senses: is there a common sensitivity? *Chem Senses*. 37(4):371–378. doi: [10.1093/chemse/bjr114](https://doi.org/10.1093/chemse/bjr114).
- Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, et al. Forthcoming. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol*. doi: [10.1001/jamaneurol.2020.1127](https://doi.org/10.1001/jamaneurol.2020.1127).
- Menni C, Valdes A, Freydin MB, Ganesh S, El-Sayed Moustafa J, Visconti A, Hysi P, Bowyer RCE, Mangino M, Falchi M, et al. Forthcoming. Real-time tracking of self-reported symptoms to predict potential COVID-19. *Nat Med*. doi: [10.1038/s41591-020-0916-2](https://doi.org/10.1038/s41591-020-0916-2).
- Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Forthcoming. Smell dysfunction: a biomarker for COVID-19. *Int Forum Allergy Rhinol*. doi: [10.1002/alf.22587](https://doi.org/10.1002/alf.22587).
- Pellegrino R, Cooper KW, Pizio A, Bhutani S, Parma V. Forthcoming. Corona viruses and the chemical senses: past, present, and future. *Chem Senses*. 45(6):415–422.
- Quint C, Temmel AF, Schickinger B, Pabinger S, Ramberger P, Hummel T. 2001. Patterns of non-conductive olfactory disorders in eastern Austria: a study of 120 patients from the Department of Otorhinolaryngology at the University of Vienna. *Wien Klin Wochenschr*. 113(1–2):52–57.
- Schwob JE, Saha S, Youngentob SL, Jubelt B. 2001. Intranasal inoculation with the olfactory bulb line variant of mouse hepatitis virus causes extensive destruction of the olfactory bulb and accelerated turnover of neurons in the olfactory epithelium of mice. *Chem Senses*. 26(8):937–952.
- Seiden AM. 2004. Postviral olfactory loss. *Otolaryngol Clin North Am*. 37(6):1159–1166.
- Stamps JJ, Bartoshuk LM, Heilman KM. 2013. A brief olfactory test for Alzheimer’s disease. *J Neurol Sci*. 333(1–2):19–24.
- Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F, et al.; HCA Lung Biological Network. 2020. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med*. 26(5):681–687.
- Swedish Public Health Authority. 2020a. Uppdaterad modellering av spridningen av covid-19 i Stockholms län. Available from: <https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/april/uppdaterad-modellering-av-spridningen-av-covid-19-i-stockholms-lan/>. Accessed 30 April 2020.
- Swedish Public Health Authority. 2020b. Gemensamma författningssamlingenavseende hälso- och sjukvård, socialtjänst, läkemedel, folkhälsa m.m. Available from: <https://www.folkhalsomyndigheten.se/contentassets/29ba284eac2e454884737b1bb7a0aecf/foreskrifter-om-andring-i-hslf-fs-2015-8.pdf>. Accessed 30 April 2020.
- Walker A, Hopkins C, Surda P. Forthcoming. The use of google trends to investigate the loss of smell related searches during COVID-19 outbreak. *Int Forum Allergy Rhinol*. doi: [10.1111/alf.22580](https://doi.org/10.1111/alf.22580).
- Wheeler DL, Athmer J, Meyerholz DK, Perlman S. 2017. Murine olfactory bulb interneurons survive infection with a neurotropic coronavirus. *J Virol*. 91(22):e01099–17.
- World Health Organization. 2020. Coronavirus. Available from: <https://www.who.int/health-topics/coronavirus>. Accessed 30 April 2020.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 579(7798):270–273.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al.; China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 382(8):727–733.